HPV vaccination intention among male clients of a large STI outpatient clinic in Amsterdam, the Netherlands  by Marra, E. et al.
Contents lists available at ScienceDirect
Papillomavirus Research
journal homepage: www.elsevier.com/locate/pvr
HPV vaccination intention among male clients of a large STI outpatient
clinic in Amsterdam, the Netherlands
E. Marraa,1, C.J. Albertsa,d,1, G.D. Zimetb, T.G.W.M. Paulussenc, T. Heijmana,
A.A. Hogewoninga,f, G.J.B. Sondera,d, J.S. Fennemaa,2, H.J.C. de Vriesa,e,f,
M.F. Schim van der Loeﬀa,d,⁎
a Department of Infectious Diseases, Public Health Service Amsterdam, Nieuwe Achtergracht 100, 1018 WT Amsterdam, the Netherlands
b Section of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States of America
c Expertise Center Child Health, Netherlands Organization for Applied Scientiﬁc Research (TNO), Leiden, the Netherlands
d Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
e Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
f Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
A R T I C L E I N F O
Keywords:
HPV
Vaccination
Men
Intention
Out-of-pocket payment
MSM
The Netherlands
A B S T R A C T
We explored HPV vaccination intention and its determinants among male clients of the sexually transmitted
infections (STI) clinic in Amsterdam. In 2015, male clients aged ≥18 years were invited to complete a web-based
questionnaire regarding HPV vaccination intention and socio-psychological determinants. Determinants (scale
−3 to +3) were assessed with linear regression, stratiﬁed for men who have sex with men (MSM) (including men
who have sex with men and women) and men who only have sex with women (MSW). Additionally, we explored
the eﬀect of out-of-pocket payment on intention.
Of 1490 participants (median age 33 years [IQR:25–44]), 1,053(71%) were MSM. HPV vaccination intention
was high (mean 1.68, 95%CI:1.55–1.81 among MSW; mean 2.35, 95%CI:2.29–2.42 among MSM). In
multivariable analyses, socio-psychological determinants had similar eﬀects on intention in both groups
(R2=0.70 among MSW; R2=0.68 among MSM), except for subjective norms, self-eﬃcacy, and HPV knowledge
(signiﬁcantly stronger associations among MSW). HPV vaccination intention decreased signiﬁcantly when
vaccination would require out-of-pocket payment; intention was negative at the current list price (€350). HPV
vaccination intention among male clients of the Amsterdam STI-clinic is high and variance in intention was
mostly be explained by socio-psychological factors. Out-of-pocket payment had a strong negative eﬀect on HPV
vaccination intention.
1. Introduction
More than 80% of sexually active people get infected with the
human papillomavirus (HPV) at least once in their life time [1].
Persistent HPV infections can cause anogenital warts, and cervical-,
vaginal-, vulvar-, anal-, penile-, and head-and-neck cancer. Vaccination
is available and found to be eﬀective and safe for the prevention of HPV
infection and many of its precancerous and cancerous sequelae [2–7].
In many countries, girls are vaccinated against HPV in order to prevent
cervical cancer [8]. Vaccinating girls inﬂuences the HPV-related
disease burden among women and, indirectly via herd immunity,
among men who have sex with women [9,10]. Men who have sex with
men (MSM) do not proﬁt from vaccinating girls, but they are at
increased risk of HPV-induced cancer, notably anal cancer (incidence
of 5.1 per 100,000 person-years among HIV-negative MSM, rising to
77.8 per 100,000 person-years among HIV-positive MSM in the
HAART-era) [11].
In the Netherlands HPV vaccination is currently only oﬀered to
girls in the year they become 13 years of age. From 2014 onwards a full
course of vaccination among 12–13 year old girls requires two doses.
The uptake has been low, approximately 60% [12], providing limited
herd protection for men who have sex with women [9,10]. A study on
the eﬀect of gender-neutral HPV vaccination in the Netherlands
suggested that it could be cost-eﬀective to oﬀer HPV vaccination to
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boys and girls in the year they turn 13 years old [9]. An alternative
strategy would be to start with targeted vaccination, in which the HPV
vaccination is oﬀered to men at Sexually Transmitted Infections (STI)
clinics, like is being introduced in the UK [13,14]. Previous studies
indicate that the intention to receive an HPV vaccination diﬀers widely
among MSM and MSW (men who have sex with only women); ranging
from 36% to 88% in MSM [15–22] and from 37% to 70% in MSW [23–
25]. Additionally, MSM seem to have a higher intention to receive HPV
vaccination compared to MSW [25,26]. In the Netherlands it is
currently unknown to what degree men would be interested in getting
vaccinated against HPV, and whether targeted vaccination would need
diﬀerent communication strategies for MSW and MSM. The aim of this
study was to investigate the acceptability of HPV vaccination and
determinants of vaccination intention among male clients, separate for
MSW and MSM, of the STI clinic of the Public Health Service in
Amsterdam, the Netherlands.
2. Methods
2.1. Study participants
From June through October 2015, male clients of the STI clinic of
the Public Health Service in Amsterdam were invited to participate in
the HP4V (human papillomavirus preparedness for vaccination) study.
Male clients were invited to participate at three separate time points
before, during, and after their visit to the STI clinic: in their appoint-
ment conﬁrmation email, through a ﬂyer handed out at the reception at
the entrance of the STI clinic, and in the email in which they received
their STI-test results.
Men were eligible for participation if they were aged 18 years or
older and conversant in Dutch or English. After completing the
questionnaire, men received 10 condoms to thank them for their
participation. Participants provided informed consent by completing
the questionnaire. Ethical clearance for this study was obtained from
the Medical Ethics Committee of the Academic Medical Center (AMC)
[A1 15 0120].
2.2. Data collection
Participants completed an anonymous self-administered web-based
questionnaire addressing HPV vaccination intention, socio-psycholo-
gical determinants of HPV vaccination intention, HPV knowledge,
socio-demographic characteristics, health related characteristics and
sexual behavior characteristics. Participants were able to complete the
questionnaire, either on their mobile phone or on a computer, in
approximately 10 min.
2.3. Questionnaire
Prior to the survey, in April and May 2015, ﬁve one-on-one
interviews focusing on HPV vaccination intention and related percep-
tions were conducted with male clients of the STI clinic in Amsterdam.
Based on the one-on-one interviews, a standardized questionnaire on
HPV vaccination decision making was adapted for this study popula-
tion [27–29]. The Reasoned Action Approach [30–32], Social Cognitive
Theory [33], and the Health Belief Model [34] provided the framework
for hypothesizing the pathways inﬂuencing HPV-vaccination decision
making. Within this framework, intention is considered to directly
impact actual behavior and was therefore used as a surrogate marker
for behavior, as HPV vaccination is not routinely oﬀered to males (yet).
Intention was assessed with two 7-point Likert-type items (ranging
from −3 up to +3) and combined to one score (Cronbach α=0.95). Most
constructs were assessed by multiple Likert-type scaled items (see
Supplementary Table 1 for more detail). Composite scores of con-
structs measured with multiple items were only computed if
Cronbach's Alpha exceeded 0.60 (Supplementary Table 1).
Demographic characteristics measured included age and educational
level. Sexual behavior characteristics included the number of male and
female sex partners in the preceding 6 months and lifetime. Health
related characteristics included medical history (HIV-status and his-
tory of anogenital warts) and HPV related variables (knowledge about
HPV, friends with a history of anogenital warts, friends with (a history
of) penile/anal cancer).
2.4. Impact of out-of-pocket payment
We asked the intention to get vaccinated after all the socio-
psychological questions were posed, and again after the concept of
out-of-pocket payment for HPV vaccination was introduced. The study
period was divided in four time periods of approximately six weeks.
Dependent on the period of inclusion a diﬀerent amount of out-of-
pocket payment (€50; €100; €200; €350) was proposed.
2.5. Stratiﬁcation based on sexual behavior
To assess whether MSW and MSM would proﬁt from a tailored
HPV vaccination campaign, we performed separate analyses for MSW
and MSM. Based on reported sexual behavior in the preceding 6
months two risk groups were created: those who reported at least one
male sex partner in the preceding 6 months were categorized as MSM,
whereas those reporting sex with only female partners in the preceding
6 months were categorized as MSW. In total, 98 (7%) of all participants
reported sexual contact with at least one male and one female partner
in the preceding six months, this is 9.3% of the MSM population
(N=1053). All individuals reported at least one sexual partner.
2.6. Statistical analyses
We assessed which proportion of male clients participated in the
study. We compared the main demographics of the total population of
male clients who attended the STI clinic during the study period to
those participating, using Chi-squared tests and Wilcoxon rank sum
tests.
Baseline characteristics of the study population and HPV vaccina-
tion intention were explored using descriptive statistics. Univariate
associations between socio-psychological factors, socio-demographic
characteristics, sexual risk behavioral and health related characteristics
with the outcome were computed by Pearson's r for continuous social-
psychological variables, Chi-squared tests for categorical variables, and
Wilcoxon rank sum tests for continuous sexual behavioral variables.
Two-step multivariable linear regression analyses were used to
assess the determinants of HPV vaccination intention when the
vaccination was oﬀered free of charge. In the ﬁrst step, all socio-
psychological variables that were associated (at P < 0.2, Wald test) with
intention in the univariate analyses were included in multivariable
analyses. A backward selection procedure was performed, leading to a
model that included socio-psychological determinants signiﬁcantly
associated with HPV vaccination intention (at P < 0.05). In the second
step, sociodemographic characteristics, health related characteristics,
and sexual behavioral characteristics (univariately associated with
intention at P < 0.20) were added to the model obtained in step one,
using a backward selection procedure. Regardless of the eﬀect of socio-
demographic characteristics, health related characteristics, and sexual
behavioral characteristics on the socio-psychological determinants,
socio-psychological determinants obtained in the ﬁrst step remained
in the model. Multicollinearity was tested by assessing the variance
inﬂation factor of all variables included in the multivariable model.
Finally, determinants found to be signiﬁcantly associated with inten-
tion in the ﬁnal model including MSW and in the ﬁnal model including
MSM where combined into one model. In this combined model we
tested for interaction between these determinants and risk group. The
rationale for testing for interaction was to assess whether MSW and
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MSM need a tailored HPV vaccination campaign.
Furthermore, we assessed the impact of a gradual increase in the
amount of out-of-pocket payment on intention in multivariable ana-
lyses. For this analyses we created a dataset containing two outcome
variables for each participant: one relating to vaccination intention
when oﬀered free of charge, and one relating to vaccination intention in
the case of a paid HPV vaccination. This dataset contained correlated
data (two records for each participant), therefore generalized estimat-
ing equations were used in univariate and multivariable linear regres-
sion analysis, using an exchangeable correlation structure and robust
variance. Finally, we assessed the impact of determinants on intention
in the model including out-of-pocket payment.
For all variables, continuous data, if available, were used, with the
exception of age. Age was categorized in age ≤26 years, 27–40 years,
and ≥41 years, because of proven safety and eﬃcacy of HPV vaccina-
tion among males ≤26 years of age [3,4]. All analyses were performed
using Stata (version 13.1; Stata Corp, College Station, Texas, USA).
3. Results
3.1. Study participation
Of the 9,301 male clients that attended the clinic in the study period
(41% MSW and 59% MSM), 1,490 (16%) participated. The participa-
tion rate was 11% among MSW and 20% among MSM. Participants
were signiﬁcantly older (median: 33 years [IQR: 25–44] vs. 29 [24–
40]), more educated (83% vs. 73% high education), more likely to be
MSM (71% vs. 57%), had a higher median number of sex partners (6
[IQR: 4–12] vs. 5[IQR:3–10]), and were more often HIV positive (13%
vs. 11%) than the total male clinic population (all P-values < 0.001;
Supplementary Table 2).
3.2. Characteristics of study population
Of the 1,490 participants, 1,053 (71%) were MSM and 437 (29%)
MSW. The median age of the participants was 33 years (IQR: 25–44);
MSW were younger than MSM (median age of 25 vs. 38 years; P <
0.001) (Table 1). Most participants had a high educational level (83%).
MSM reported signiﬁcantly more sex partners in the preceding six
months compared to MSW (median 9 [IQR: 5–18] vs. median 5 [IQR:
3–7]; P < 0.001), as well as a higher lifetime number of sex partners
(median 100 [IQR: 38–400] vs. median 23 [IQR: 10–43]; P < 0.001).
Thirteen percent of the participants was HIV-positive (1% of MSW and
18% of MSM; P < 0.001).
3.2.1. Vaccination intention
Vaccination intention among the participants was very high with a
mean vaccination intention of 2.15 (95%CI: 2.09–2.22; range −3 up to
+3). MSW had a lower vaccination intention score (mean=1.68; 95%
CI: 1.55–1.81) compared to MSM (mean=2.35; 95%CI: 2.29–2.42; P <
0.001) (Table 1).
3.2.2. Univariate linear regression analyses
Univariate linear regression analyses stratiﬁed by risk group (MSW
vs. MSM) are presented in Table 2. The following factors were
signiﬁcantly associated with HPV-vaccination intention among MSW:
all socio-psychological determinants, knowledge about HPV, a history
of anogenital warts, and having friends with a history anogenital warts.
Table 1
Baseline characteristics of the study population (N=1,490), overall and stratified by risk
group (HP4V men study, Amsterdam 2015).
Total MSW MSM P-value
(n=1490) (n=437) (n=1053)
No. % No. % No. %
Socio-demographic
characteristics
< 0.001
Median age (IQR) in
years
33 (25–
44)
25 (22–
29)
38 (28–
47)
Age < 0.001
≤26 years 485 32 263 60 222 21
27–40 years 534 36 153 35 381 36
≥41 years 471 32 21 5 450 43
Educational level 0.314
Lower
education
246 17 79 18 167 16
High
education
1,235 83 357 82 878 84
Medical history
HIV status < 0.001
HIV-negative 1,054 71 313 72 741 70
HIV-positive 194 13 6 1 188 18
Unknown or
not willing to
disclose
242 16 118 27 124 12
History of
anogenital warts
< 0.001
Yes 450 30 78 18 372 35
No 1040 70 359 82 681 65
Sexual behavior
Median no. of sex
partners
(preceding 6
months) (IQR)
6 (4–12) 5 (3–7) 9 (5–18) < 0.001
Median no. of
lifetime sex
partners (IQR)
55 (22–
201)
23 (10–
43)
100 (38–
400)
< 0.001
HPV related
variables
Knowledge about
HPV (0–7) (IQR)
5 (4–6) 5 (4–6) 6 (5–7) < 0.001
Friends with history of
anogenital warts
< 0.001
No 945 63 325 74 620 59
Yes 545 37 112 26 433 41
Friends with (a history of) anal/
penile cancer
< 0.001
No 1344 90 423 97 921 88
Yes 146 10 14 3 132 13
Mean HPV
vaccination
intention (95%
CI) (range −3 to
3)
2.15 (2.09–
2.22)
1.68 (1.55–
1.81)
2.35 (2.29–
2.42)
< 0.001
HPV vaccination
intention
< 0.001
Certainly not
(−3)
17 1 7 2 10 1
Probably not
(−2)
12 1 7 2 5 1
Maybe not
(−1)
33 2 21 5 12 1
Maybe/
Maybe not
(0)
86 6 46 11 40 4
Maybe (+1) 167 11 75 17 92 9
Probably
(+2)
298 20 96 22 202 19
Definitely
(+3)
877 59 185 42 692 66
Data was missing for: educational level (n=9).
Educational level is measured according to the Dutch education levels. Participants were
asked what their highest completed level of education was. They could choose: no
educational degree (did not finish any education), Primary school, Lower general
secondary school, Higher general secondary school, Preuniversity school, Secondary
vocational school, Higher vocational school, University, Different. Lower education
contains: no educational degree, Primary school, Lower general secondary school, Higher
general secondary school and Secondary vocational school. Higher education included:
Preuniversity school, Higher vocational school, and University.
Abbreviations: IQR=Interquartile range; HIV=human immunodeficiency virus;
HPV=human papillomavirus; MSW=men who have sex with only women; MSM=men
who have sex with men.
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Among MSM, all socio-psychological determinants, all socio-demo-
graphic characteristics, and sexual behavioral variables, were found to
be signiﬁcantly associated with intention, except educational level,
having friends with (a history of) anogenital warts, and having friends
with (a history of) anal or penile cancer (Table 2).
3.2.3. Multivariable linear regression analyses
In multivariable linear regression analysis we found that among
MSW attitude was one of the strongest predictors of HPV vaccination
intention (Beta 0.57; 95%CI 0.49–0.66). Additionally, self-eﬃcacy
(Beta 0.29; 95%CI 0.23–0.35), anticipated regret (Beta 0.12; 95%CI
0.05–0.19), subjective norm (Beta 0.12; 95%CI 0.05–0.19), and
descriptive norm (Beta 0.11; 95%CI 0.01–0.21) signiﬁcantly improved
the model, which altogether had a high degree of explained variance
(R2=0.70). When demographics and sexual behavior variables were
added, age, lifetime number of sex partners, and knowledge about HPV
increased the explained variance in MSW somewhat (R2=0.71)
(Table 2). Multicollinearity was not a problem for this model, since
the variance inﬂation factor was < 2.0 for all variables.
Also among MSM, attitude showed the strongest association with
HPV vaccination intention (Beta 0.66; 95%CI 0.61–0.71; P < 0.001). In
addition to attitude, self-eﬃcacy (Beta 0.19; 95%CI 0.15–0.24),
descriptive norm (Beta 0.10; 95%CI 0.06–0.15), anticipated regret
(Beta 0.09; 95%CI 0.05–0.13), and negative outcome expectancies
(Beta −0.03; 95%CI −0.06 to 0.00) were signiﬁcantly associated with
HPV vaccination intention. Together, these socio-psychological deter-
minants had a high explained variance (R2=0.68). Age and the lifetime
number of sexual partners were also associated with HPV vaccination
intention among MSM but did not increased the explained variance
(R2=0.68) (Table 2). The variance inﬂation factor was < 2.0 for all
variables, indicating that multicollinearity was not posing problems in
this model.
To assess whether the association of this ﬁnal set of determinants of
intention varied by risk group we tested for interaction in a model
combining MSW and MSM. Most determinants had similar eﬀects on
intention, except for subjective norm (P=0.002), self-eﬃcacy (P=0.002)
and knowledge (P < 0.001) which all three had a stronger eﬀect in the
MSW group than in the MSM group.
We also analyzed predictors of intention in a model combining
MSW and MSM. Overall a similar pattern of important determinants
was seen in stratiﬁed analysis. Notably, sexual behavior, being MSM or
MSW, was statistically signiﬁcant associated with HPV vaccination
intention in the multivariable model (Supplementary Table 3).
3.3. The eﬀect of payment on vaccination intention
All socio-psychological questions up to the payment question
implied that HPV vaccination would be free of charge (as is currently
the case in the Netherlands for all 12–13 year old girls). During four
diﬀerent study periods diﬀerent amount of out-of-pocket payments
were proposed. Participants from these four periods were comparable
concerning demographics, sexual behavioral characteristics, and HPV
vaccination intention (data not shown). For each subsequent increase
in the required amount of out-of-pocket payment for HPV vaccination,
the mean HPV vaccination intention decreased signiﬁcantly (Fig. 1).
The mean vaccination intention among MSW was: €0: 1.68 (95%CI
1.55–1.81); €50: 0.73 (95%CI 0.52–0.95); €100: 0.06 (95%CI −0.20 to
0.32); €200: −1.04(95%CI −1.27 to −0.81); €350: −1.35 (95%CI −1.53
to −1.17). The mean vaccination intention among MSM was: €0: 2.35
(95%CI 2.29–2.42); €50: 1.75 (95%CI 1.61–1.88); €100: 1.07 (95%CI
0.90–1.23); €200: 0.16(95%CI 0.00–0.33); €350: −0.49 (95%CI −0.65
to −0.32). The drop in intention was signiﬁcantly stronger among MSW
compared to MSM (P=0.003). Interestingly, the intention became
negative if the three doses would cost €200 or more in the MSW group
(mean −1.04: 95%CI: −0.81 to −1.27) and became negative in the
MSM group when the proposed cost was €350 (mean −0.49: 95%CI:
−0.32 to −0.65). The eﬀect of out-of-pocket payment on intention was
similar in univariate analysis and in multivariable analysis (when it was
added to the model obtained previously) (Supplementary Table 4). All
other associations remained similar, except for age among MSM which
had a signiﬁcantly stronger impact on intention when compared to the
model when HPV vaccination was oﬀered free of charge.
4. Discussion
HPV vaccination intention among male clients of the STI clinic in
Amsterdam, the Netherlands, was high: a mean vaccination intention
of 2.15 (95%CI: 2.09–2.22). Furthermore, MSM (including both men
who have sex with only men and men who have sex with both men and
women) included in this study had a higher vaccination intention than
included MSW. This study revealed that attitude towards HPV vaccina-
tion and self-eﬃcacy (to what extent does one consider oneself able to
come to the clinic three times to get vaccinated) were the most
important determinants of HPV vaccination intention among both
MSW and MSM. Socio-psychological determinants explained the
variance of HPV vaccination intention among male clients of the STI
outpatient clinic in Amsterdam to a large degree. Overall, most
determinants had the same eﬀect on intention in the MSW and MSM
groups, except for subjective norm, self-eﬃcacy, and knowledge which
all three were stronger in the MSW group than in the MSM group.
When intention was assessed in the situation where an out-of-pocket
payment would be required, HPV vaccination intentions decreased
drastically. At the current list price (around €350 for a complete series
of three vaccinations), the mean vaccination intention was negative for
both MSW and MSM.
This study showed a higher HPV vaccination intention (90%)
compared to other studies exploring the intention to receive the HPV
vaccination when vaccination is oﬀered free of charge (range 36–88%)
[15–22]. Nadarzynski et al. [22] attributed the lower intention to the
limited awareness of HPV. In the present study, knowledge was
generally high and had a signiﬁcant eﬀect on intention in the MSW
group, yet no eﬀect in the MSM group was found which may reﬂect a
lack of awareness among a substantial proportion in this group.
Furthermore, our results conﬁrm prior research showing a higher
vaccination intention among MSM compared to MSW [25,26].
We conﬁrm that socio-psychological determinants are the most
important determinants of HPV vaccination intention [28,29,35–37].
Diﬀerences across studies in strength of socio-psychological determi-
nants on the association with HPV vaccination intention could be
explained by cultural diﬀerences of study populations and diﬀerences
in the way vaccinations are typically oﬀered in countries (e.g. costs,
opportunistic/organized, opt-out/in). Furthermore, as found in earlier
studies [28,29,35–37], probing the whole spectrum of socio-psycholo-
gical determinants inﬂuencing intention, attitude appeared to be one of
the strongest predictors of HPV vaccination intention among both
MSW and MSM. In contrast to what we have found, self-eﬃcacy is less
often found to play a crucial role on HPV vaccination intention in other
studies, while social inﬂuences are found to be important determinants
[24,37,38]. Other attitudinal constructs like outcome beliefs and
anticipated regret were also signiﬁcantly associated but their associa-
tions were less strong. As could be expected from theory, these
determinants overlapped with general attitude to a great extent, yet
they remain important targets for improving HPV vaccination related
attitudes.
In contrast to what has been found in previous studies on
vaccination acceptability in the Netherlands [28,39], we also found
self-eﬃcacy to be a strong predictor of intention. However, this can be
considered as expected, as going to the STI outpatient clinic three times
to get a vaccination may pose a barrier as it can be time consuming or
STI clinic visits could be perceived as embarrassing.
Not surprisingly, out-of-pocket payment had a signiﬁcantly strong
negative eﬀect on HPV vaccination intention in both groups. The
E. Marra et al. Papillomavirus Research 2 (2016) 178–184
181
Table 2
Association between socio-psychological determinants, socio-demographic characteristics, health related characteristics, and sexual behavioral characteristics with vaccination intention
by risk group (HP4V men study, Amsterdam 2015).
MSW (N=437) MSM (N=1053)
Univariable linear regression
analysis
Multivariable linear regression
analysisa
Univariable linear regression
analysis
Multivariable linear regression
analysisa
Beta (95%CI) P-value Beta (95%CI) P-
value
Beta (95%CI) P-value Beta (95%CI) P-value
Sociopsychological determinants
Risk perception 0.30 (0.21–
0.40)
< 0.001 0.20 (0.16–
0.25)
< 0.001
Attitude towards HPV
vaccination
0.90 (0.83–
0.97)
< 0.001 0.57 (0.49–
0.66)
<
0.001
0.81 (0.78–
0.85)
< 0.001 0.66 (0.61–
0.71)
<
0.001
Negative outcome expectancies
of HPV vaccination
0.24 (0.15–
0.33)
< 0.001 0.15 (0.10–
0.19)
< 0.001 −0.03 (−0.06 to
0.00)
0.031
Anticipated regret about
rejecting HPV vaccination
0.55 (0.44–
0.65)
< 0.001 0.12 (0.05–
0.19)
0.001 0.47 (0.42–
0.52)
< 0.001 0.09 (0.05–
0.13)
<
0.001
Beliefs about HPV vaccination 0.22 (0.12–
0.32)
< 0.001 0.11 (0.05–
0.17)
< 0.001
Subjective norm towards HPV
vaccination
0.55 (0.45–
0.66)
< 0.001 0.12 (0.05–
0.19)
0.002 0.38 (0.32–
0.43)
< 0.001
Descriptive norm towards HPV
vaccination
0.74 (0.62–
0.88)
< 0.001 0.11 (0.01–
0.21)
0.024 0.49 (0.43–
0.56)
< 0.001 0.10 (0.06–
0.15)
<
0.001
Self-eﬃcacy expectations
towards HPV vaccination
0.61 (0.54–
0.68)
< 0.001 0.29 (0.23–
0.35)
<
0.001
0.52 (0.45–
0.58)
< 0.001 0.19 (0.15–
0.24)
<
0.001
Socio-demographic
characteristics
Age 0.128 0.019
≤26 years REF REF REF REF
27–40 years 0.26 (−0.02 to
0.54)
−0.14 (−0.31 to
0.03)
0.103 0.26 (0.08–
0.43)
0.09 (−0.02 to
0.19)
0.111
≥41 years 0.38 (−0.024 to
1.00)
−0.43 (−0.79 to
−0.07)
0.021 0.17 (−0.00 to
0.34)
−0.02 (−0.13 to
0.09)
0.711
Educational level 0.150 0.753
Lower education REF REF
High education 0.25 (−0.09 to
0.59)
−0.03 (−0.20 to
0.15)
Health related characteristics
HIV status 0.405 < 0.001
HIV-negative REF REF
HIV-positive 0.73 (−0.41 to
1.87)
0.37 (0.20–
0.54)
Unknown or not
willing to disclose
−0.05 (−0.35 to
0.24)
−0.21 (−0.42 to
−0.02)
History of anogenital warts < 0.001 0.007
No REF REF
Yes 0.75 (0.41–
1.09)
0.18 (0.05–
0.32)
Sexual behavior
Number of sexpartners in
preceding 6 monthsb
0.00 (−0.17 to
0.18)
0.993 0.08 (0.01–
0.15)
< 0.001
Lifetime number of
sexpartnersb,c
0.11 (0.00–
0.23)
0.059 0.07 (−0.00 to
0.14)
0.051 0.09 (0.06–
0.13)
< 0.001 0.03 (0.01–
0.05)
0.018
HPV related variables
Knowledge about HPV 0.17 (0.10–
0.23)
< 0.001 0.06 (0.02 to
0.10)
0.005 0.06 (0.02–
0.09)
0.003
Friends with a history
anogenital warts
0.017 0.100
No REF REF
Yes 0.37 (0.07–
0.67)
0.11 (−0.02 to
0.24)
Friends with (a history of) anal/
penile cancer
0.921 0.194
No REF REF
Yes 0.38 (−0.71 to
0.79)
0.13 (−0.07 to
0.33)
Abbreviations: HP4V=human papillomavirus preparedness for vaccination; CI=confidence interval; HIV=human immunodeficiency virus; HPV=human papillomavirus; MSW=men
who have sex with only women only; MSM=men who have sex with men.
a The multivariable analyses were executed by adding variables in two steps: (step 1) socio-psychological determinants, (step 2) medical history, sexual behavioral characteristics and
HPV related variables. R squared (R2) is a measure that indicates how well the data ﬁt a linear regression model. We found in MSW that after step 1 the R2 was 0.70 and after step 2 the
R2 was 0.71. We found in MSM the R2 to be 0.68 after step 1 and this did not change after adding the variables signiﬁcant in step 2.
b For analyses purposes lifetime number of sexual partner was log transformed.
c in MSW: number of female sex partners; in MSM: number of male sex partners.
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decrease in intention to vaccinate when out-of-pocket payment was
proposed has been well established in previous studies in men [16–
18,20,40]. When introducing costs for HPV vaccination, socio-psycho-
logical factors remained important. To our knowledge, only one other
study analyzed determinants of HPV vaccination intention among men
based on a certain payment for vaccination. Lau et al. [20] found that
knowledge about HPV, perceived severity, and perceived vaccine
eﬃcacy were associated with HPV vaccination intention given a price
of HK$1000–2000 (US$ 128–256) per shot and a total of 3 shots
within six months. The increasing intention with increasing age found
among MSM when out-of-pocket payment was required, can be
explained by generally higher socio-economic status with increasing
age, and therefore, payment for healthcare becomes more aﬀordable at
an older age. However, this increase in intention with age could also be
explained by an increased risk perception for acquiring HPV-related
diseases in (older) MSM, increasing the willingness to pay to avoid
those diseases. Unfortunately, the chance that an individual has
encountered a previous HPV infection increases with age, reducing
the eﬀectiveness of the prophylactic HPV vaccine [41].
4.1. Strengths
The strengths of this study include the large sample size, the use of
a well-tested theory based questionnaire, and the relevant clinical
sample of MSM and MSW attending STI clinics, allowing us to explore
a diverse palette of social psychological factors inﬂuencing HPV
vaccination intention. Furthermore, our ﬁnal multivariable models
had a large explained variance of intention (R2 of 0.71 in MSW and
0.67 in MSM), which suggests that the questionnaire used was able to
cover the most important predictors of intention. Next, in contrast to
most studies, we were able to test whether MSW and MSM should be
approached diﬀerently when developing an HPV vaccination interven-
tion (which we found was not necessary). Finally, this is one of the ﬁrst
studies that tested the eﬀect of diﬀerent amounts of out-of-pocket
payment on HPV vaccination intentions, stratiﬁed by risk group.
4.2. Limitations
The response rate was relatively low (16%). This can be explained
by the passive recruitment methods used in this study. Additionally,
the study population diﬀered from the total population of male clients
of the STI clinic in various demographic characteristics and in sexual
behavioral characteristics. Individuals participating in questionnaire-
based research at the STI outpatient clinic in Amsterdam are more
often higher educated [42–44] than the total client population. If
selection bias occurred, this may have biased the observed mean scores
upwards, but it will probably not have impacted the association
between determinants and intention. Additionally, income was not
assessed in this study. Income could have helped explain variance in
HPV vaccination intention, especially when considering the eﬀect of
pricing on HPV vaccination intention. Lastly, this study was based on a
hypothetical scenario since HPV vaccination for men is currently not
oﬀered in the Netherlands, although this may change in the future.
Despite its hypothetical nature, this study may help to inform future
planning strategies when introducing targeted HPV vaccinations.
4.3. Implications
In the Netherlands HPV vaccination is currently only oﬀered free of
charge to girls in the year they turn 13 years of age. Future inclusion of
boys in this vaccination program is unclear, despite the predicted
beneﬁt of vaccinating boys along with girls when the vaccination
coverage among girls remains at 60% [9]. However, Bogaards et al.
also emphasize the high burden of anal cancer among MSM that will
not be prevented even if a high HPV vaccination coverage among girls
would be reached [9]. Targeted vaccination of men, especially MSM,
visiting the STI clinic may therefore still be an approach to consider,
even more so as we showed that intention to become vaccinated is high
among men that visit the STI clinic. Therefore, high uptake can be
expected if the HPV vaccination is oﬀered free of charge. This tentative
conclusion can ﬁrst be evaluated by a pilot project among men visiting
STI clinics in the Netherlands, to demonstrate whether oﬀering HPV
vaccination at STI clinics in the Netherlands would indeed lead to a
high coverage among men at high risk. Challenges in implementing
HPV vaccination among men that have been pointed out in previous
studies suggest a focus on educating men about HPV infection,
prevention, transmission, morbidity, and mortality is required.
Emphasis should also be on health care providers to actively oﬀer
HPV vaccination to males. However, this requires men to openly
identify themselves as MSM, which is a societal challenge [45,46].
This study provides insight into what determinants should be targeted
by educational interventions promoting HPV vaccination uptake
among men at high risk for HPV and suggests that similar determi-
nants can be used for both MSW and MSM, albeit with additional
attention for the MSW when it comes to compliance (visiting the STI
clinic three times to receive all three HPV vaccinations).
5. Conclusion
HPV vaccination intention among male clients of the Amsterdam
STI clinic is very high. Most of the variance in HPV vaccination
intention among men can be explained by socio-psychological factors
and these determinants were largely similar in MSM and in MSW. In
contrast to previous HPV vaccination acceptability studies in the
Netherlands, intention was not merely attitudinally driven, but also
self-eﬃcacy played a key role. Out-of-pocket payment has a strong
negative impact on HPV vaccination intention. These results suggest
that if HPV vaccination would be oﬀered to men at STI clinics free of
charge, uptake of the HPV vaccination would be high.
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